2020 CGA Annual Meeting

Details

Registration for the Virtual CGA Annual Meeting is FREE for Members!

If you are not a member or have not renewed your membership dues for 2020 yet, please select "General Registration" where you will be given the option to join/renew your membership for CGA-IGC and access the Annual Meeting at no additional cost.

2020 CGA Annual Meeting
The 2020 CGA Annual Meeting is being held virtually November 14-15. The CGA Annual Meeting will provide critical data and information designed to keep clinicians and scientists up-to-date on new developments in hereditary gastrointestinal cancer research, including implications for physicians, nurses, and genetic counselors to make informed decisions about the prevention, diagnosis, and treatment of patients with hereditary gastrointestinal cancer syndromes. The CGA Annual Meeting, in its 24th year, is a conference directed to colorectal surgeons, medical oncologists, gastroenterologists, researchers, geneticists, nurses, colorectal cancer registry coordinators, genetic counselors, psychologists and other professionals involved in the care of individuals with hereditary gastrointestinal cancer, including colorectal, esophageal, pancreatic, gastric, and small bowel cancers.

Who Should Attend

The 2020 CGA Annual Meeting will be directed to colorectal surgeons, medical oncologists, gastroenterologists, researchers, geneticists, nurses, colorectal cancer registry coordinators, genetic counselors, psychologists and other professionals involved in the care of individuals with hereditary gastrointestinal cancer, including colorectal, esophageal, pancreatic, gastric, and small bowel cancers.

Objectives
After completing this activity, participants will be able to do the following:

Summarize recent research on the basic biology of gastrointestinal cancer development, including modifiers of the hereditary phenotypes
Describe potential implications for clinical practice
Implement new approaches to screening and preventing gastrointestinal cancers
Summarize the evidence for new diagnostics, devices, and pharmaceuticals
Describe the impact of newly discovered genes and the use of recently introduced gene panels to diagnose and manage hereditary gastrointestinal cancer syndromes
Institute use of clinical and genetic modifiers of the hereditary cancer risk in their clinical practice
Define the changing care models for diagnosis and management of various hereditary cancer syndromes
List the surgical approaches to hereditary gastrointestinal cancer syndromes for both treatment and prophylaxis
Describe patient criteria for referral for surgery that offers optimal outcomes

Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Collaborative Group of the Americas on Inherited Colorectal Cancer. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Society of Genetic Counselors (NSGC) has authorized CGA-IGC to offer up to TBD CEUs or TBD Category 1 contact hours for the activity 2020 CGA-IGC Annual Meeting. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

This educational activity is supported by educational grants from AstraZeneca and Pfizer.